

Wolf-Henning Boehncke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2981910/publications.pdf>

Version: 2024-02-01

63
papers

4,965
citations

236612

25
h-index

110170

64
g-index

69
all docs

69
docs citations

69
times ranked

5961
citing authors

#	ARTICLE	IF	CITATIONS
1	Psoriasis. <i>Lancet, The</i> , 2015, 386, 983-994.	6.3	1,793
2	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	2.9	726
3	The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1682.	2.2	312
4	Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF± inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1115-1125.	6.3	211
5	Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. <i>Frontiers in Immunology</i> , 2018, 9, 579.	2.2	201
6	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet, The</i> , 2018, 391, 2213-2224.	6.3	159
7	Etiology and Pathogenesis of Psoriasis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 665-675.	0.8	130
8	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. <i>Frontiers in Immunology</i> , 2019, 10, 3096.	2.2	122
9	S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 645-669.	0.4	107
10	IL-25 (IL-17E) in epithelial immunology and pathophysiology. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 40-52.	1.5	74
11	Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1970-1980.	0.3	73
12	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
13	Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 295-311.	2.9	57
14	Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation. <i>PLoS ONE</i> , 2017, 12, e0180853.	1.1	54
15	Immunogenicity of biologic therapies: causes and consequences. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 513-523.	1.3	51
16	IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1697-1705.	0.5	48
17	Autoreactive T-Lymphocytes in Inflammatory Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1198.	2.2	48
18	Circadian clocks guide dendritic cells into skin lymphatics. <i>Nature Immunology</i> , 2021, 22, 1375-1381.	7.0	47

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021, 60, 2109-2121.	0.9	44
20	IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1732-1742.e17.	0.3	42
21	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	1.8	36
22	Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line. <i>Nature Communications</i> , 2019, 10, 4097.	5.8	35
23	IL-17E (IL-25) and IL-17A Differentially Affect the Functions of Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1379-1389.e2.	0.3	35
24	S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 806-813.	0.4	32
25	Regulatory cells in the skin: Pathophysiologic role and potential targets for anti-inflammatory therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1302-1310.	1.5	32
26	German S3 Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm " Part 1: Treatment goals and treatment recommendations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 934-150.	0.4	30
27	Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 5-13.	1.3	25
28	Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2019, 95, 20-27.	1.0	23
29	More than skin-deep: the many dimensions of the psoriatic disease. <i>Swiss Medical Weekly</i> , 2014, 144, w13968.	0.8	23
30	Cytokines of the IL-17 family in psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 675-681.	0.4	22
31	German S3 Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm " Part 2: Treatment monitoring and specific clinical or comorbid situations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1092-1115.	0.4	20
32	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	1.0	18
33	Psoriasis and Psoriatic Arthritis: Flip Sides of the Coin?. <i>Acta Dermato-Venereologica</i> , 2016, 96, 436-441.	0.6	18
34	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , 2020, 7, 617-637.	1.1	17
35	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020, 15, e0235091.	1.1	17
36	Targeted cutaneous delivery of etanercept using Er:YAG fractional laser ablation. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119234.	2.6	16

#	ARTICLE	IF	CITATIONS
37	Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study. <i>Rheumatology and Therapy</i> , 2018, 5, 423-436.	1.1	15
38	Dysfunctional Keratinocytes Increase Dermal Inflammation in Systemic Sclerosis: Results From Studies Using Tissue-Engineered Scleroderma Epidermis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1311-1317.	2.9	15
39	Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2301-2305.	1.0	14
40	Reversal of Murine Epidermal Atrophy by Topical Modulation of Calcium Signaling. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1599-1608.	0.3	12
41	Recognition of early melanoma: a monocentric dermoscopy follow-up study comparing <i>de novo</i> melanoma with nevus-associated melanoma. <i>International Journal of Dermatology</i> , 2018, 57, 692-702.	0.5	12
42	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. <i>RMD Open</i> , 2022, 8, e002195.	1.8	11
43	The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development. <i>Experimental Dermatology</i> , 2020, 29, 71-78.	1.4	10
44	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.3	10
45	Mechanotransduction in Skin Inflammation. <i>Cells</i> , 2022, 11, 2026.	1.8	10
46	Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2014, 41, 1194-1196.	1.0	9
47	Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal <i>BRAF</i> inhibition. <i>Cancer Medicine</i> , 2017, 6, 1652-1664.	1.3	9
48	Dermal adipocytes™ claim for fame in psoriasis. <i>Experimental Dermatology</i> , 2017, 26, 392-393.	1.4	9
49	Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11911.	0.5	8
50	Perspective: Don't be superficial. <i>Nature</i> , 2012, 492, S55-S55.	13.7	6
51	Pathogenesis-oriented therapy of psoriasis using biologics. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1463-1473.	1.4	6
52	IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in systemic sclerosis epidermis. <i>Rheumatology</i> , 2022, 61, 4558-4569.	0.9	5
53	GRAPPA 2013 Basic/Translational/Clinical Science Update: Comorbidity Monitoring. <i>Journal of Rheumatology</i> , 2014, 41, 1224-1226.	1.0	4
54	LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan. <i>PLoS ONE</i> , 2021, 16, e0245954.	1.1	4

#	ARTICLE	IF	CITATIONS
55	GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: A Meeting Report. Journal of Rheumatology, 2014, 41, 1197-1199.	1.0	3
56	GRAPPA 2015 Research and Education Project Reports. Journal of Rheumatology, 2016, 43, 979-985.	1.0	3
57	GRAPPA Trainees Symposium 2017: A Report from the GRAPPA 2017 Annual Meeting. Journal of Rheumatology, 2018, 94, 4-10.	1.0	3
58	GRAPPA Trainees Symposium 2018: A Report from the GRAPPA 2018 Annual Meeting. Journal of Rheumatology, 2019, 95, 4-10.	1.0	3
59	Presidential Round Table: A Report from the GRAPPA Annual Meeting. Journal of Rheumatology, 2016, 43, 986-989.	1.0	2
60	In vivo reflectance confocal microscopy: a useful non-invasive tool to assess the response to isolated limb perfusion for superficial pigmented melanoma in-transit metastatic disease. Dermatology Practical and Conceptual, 2017, 7, 47-49.	0.5	1
61	AB0745â€¦ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL. , 2019, , .		0
62	FRI0440â€¦THE EFFECT OF GUSELKUMAB ON PASDAS, GRACE INDEX, MCPDAI, AND DAPSA: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. , 2019, , .		0
63	FRI0452â€¦TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES. , 2019, , .		0